

Pathology & Oncology Research

C-MYC, HIF-1 α , ERG, TKT, and GSTP1: an axis in prostate cancer?

--Manuscript Draft--

Manuscript Number:	
Full Title:	C-MYC, HIF-1 α , ERG, TKT, and GSTP1: an axis in prostate cancer?
Article Type:	Original Article
Keywords:	Prostate cancer; c-myc; HIF-1 α ; GSTP1, TKT, ERG.
Corresponding Author:	Laura Boldrini, Ph.D University of Pisa ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Pisa
Corresponding Author's Secondary Institution:	
First Author:	Laura Boldrini, PhD
First Author Secondary Information:	
Order of Authors:	Laura Boldrini, PhD Riccardo Bartoletti, MD Mirella Giordano, PhD Francesca Manassero, MD Cesare Selli, MD Marco Panichi, MD Luca Galli, MD Fabiola Farci, MD Pinuccia Faviana, MD
Order of Authors Secondary Information:	
Funding Information:	
Abstract:	<p>Purpose: To analyze putative biomarkers for prostate cancer (PCA) characterization, the second leading cause of cancer-associated mortality in men.</p> <p>Methods: Quantification of the expression level of c-myc and HIF-1α mRNA with Real-Time PCR technology was performed in seventy-two prostate cancer specimens. A cohort of 497 prostate cancer patients from The Cancer Genome Atlas (TCGA) database was further analyzed, in order to test our hypothesis.</p> <p>Results: We found that high c-myc level was significantly associated with HIF-1α elevated expression ($p=0.008$) in our 72 samples. Statistical analysis of 497 TCGA prostate cancer specimens confirmed the strong association ($p=0.0005$) of c-myc and HIF-1α expression levels, as we found in our series. Moreover, we found high c-myc levels significantly associated with low GSTP1 expression ($p=0.01$), with high TKT expression ($p<0.0001$). High TKT levels were found in TCGA samples with low GSTP1 mRNA ($p<0.0001$), as shown for c-myc, and with ERG increased expression ($p=0.02$). Finally, samples with low GSTP1 expression displayed higher ERG mRNA levels than samples with high c-myc ($p<0.0001$), as above shown for c-myc.</p> <p>Conclusions: Our study emphasizes the notion of a potential value of HIF-1α and c-myc as putative biomarkers in prostate cancer; moreover TCGA data analysis showed a putative crosstalk between c-myc, HIF-1α, ERG, TKT, and GSTP1, suggesting a potential use of this axis in prostate cancer.</p>
Suggested Reviewers:	Rodolfo Montironi

R.Montironi@univpm.it
Great expertise in prostate cancer

Truls E Bjerklund Johansen
t.e.b.johansen@medisin.uio.no
Expertise in urinary disease.

Title page***C-MYC, HIF-1 α , ERG, TKT, and GSTP1: an axis in prostate cancer?***

Laura Boldrini¹, Bartoletti R², Giordano M¹, Manassero F³, Selli C², Panichi M⁴, Galli L⁵, Farci F¹, and Pinuccia Faviana¹.

¹Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.

²Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy.

³Division of Urology, Pisa University, Pisa, Italy.

⁴Department of Radiotherapy, Pisa University, Pisa, Italy.

⁵Division of Medical Oncology, Pisa University, Pisa, Italy.

Correspondence to:

Dr. Laura Boldrini

Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126 Pisa, Italy.

Phone: +39 050 997849; Fax: +39 050 992983.

e-mail: laura.boldrini@med.unipi.it

Acknowledgements

Not applicable.

Abstract

Purpose: To analyze putative biomarkers for prostate cancer (PCA) characterization, the second leading cause of cancer-associated mortality in men.

Methods: Quantification of the expression level of *c-myc* and *HIF-1 α* mRNA with Real-Time PCR technology was performed in seventy-two prostate cancer specimens. A cohort of 497 prostate cancer patients from The Cancer Genome Atlas (TCGA) database was further analyzed, in order to test our hypothesis.

Results: We found that high *c-myc* level was significantly associated with *HIF-1 α* elevated expression ($p=0.008$) in our 72 samples. Statistical analysis of 497 TCGA prostate cancer specimens confirmed the strong association ($p=0.0005$) of *c-myc* and *HIF-1 α* expression levels, as we found in our series. Moreover, we found high *c-myc* levels significantly associated with low *GSTP1* expression ($p=0.01$), with high *TKT* expression ($p<0.0001$). High *TKT* levels were found in TCGA samples with low *GSTP1* mRNA ($p<0.0001$), as shown for *c-myc*, and with *ERG* increased expression ($p=0.02$). Finally, samples with low *GSTP1* expression displayed higher *ERG* mRNA levels than samples with high *GSTP1* score ($p<0.0001$), as above shown for *c-myc*.

Conclusions: Our study emphasizes the notion of a potential value of *HIF-1 α* and *c-myc* as putative biomarkers in prostate cancer; moreover TCGA data analysis showed a putative crosstalk between *c-myc*, *HIF-1 α* , *ERG*, *TKT*, and *GSTP1*, suggesting a potential use of this axis in prostate cancer.

Keywords:

Prostate cancer; *c-myc*; *HIF-1 α* ; *GSTP1*, *TKT*, *ERG*.

Introduction

Prostate cancer (PCA) is the second leading cause of cancer-associated mortality in men. One of the greatest challenges in the management of prostate cancer patients is identifying biomarkers to predict clinical outcome. Gleason score, tumor stage, margin status and PSA levels represent classical prognostic factors, but they are insufficient for discriminating between patients with indolent tumors that are unlikely to progress and may be potentially over-treated and patients with aggressive, fatal disease.

The activation of the proto-oncogene *myc* is one of the earliest molecular alterations in prostate cancer [1], and it may be considered an important biomarker in the early detection and diagnosis of this disease. Myc protein expression has been described as detected by immunohistochemistry [2], as well as upregulation of *myc* at the mRNA level [3], but the mechanism responsible in prostate cancer remains unclear. Myc is able to directly and indirectly regulate the transcription of several genes and pathways.

HIF-1 α overexpression has been associated with shorter time to biochemical recurrence, metastasis, and chemoresistance in prostate cancer patients [4-6]. Considering the role of HIF-1 α in the activation of several cancer-related pathways, it should be an attractive target for cancer therapy [7], and a better knowledge of HIF-1 α regulation in prostate cancer could provide better outcomes and therapeutic chances for men with prostate cancer.

The occurrence of prostate cancer has been associated with environmental factors, such as Glutathione S-transferase P1 (GSTP1), an enzyme of the glutathione S-transferases (GSTs) family modulating signaling pathways involved in cell proliferation, differentiation, and apoptosis. GSTP1 overexpression has been suggested to play a protective role in prostate cancer *in vitro* and *in vivo* through targeting *c-myc* [8].

Transketolase (TKT) is considered involved in so-called tumor metabolic reprogramming, and TKT activity is increased in rapidly growing breast cancer cells [9], but its role in prostate cancer and the putative crosstalk with *c-myc* has not yet been analysed.

In the last decade, the discovery of oncoproteins and gene rearrangements/fusion genes associated to the progression of prostate cancer, has brought a great progress in identifying new modalities of treatment. One of the most common rearrangements in prostate cancer is the TMPRSS2-ERG fusion. *ERG* has been reported as an early event in prostate carcinogenesis, but its role in prostate cancer progression is still controversy [10-18].

From the perspective above, the aim of this study was to examine simultaneously expression of *c-myc* and *HIF-1 α* in

our 72 prostate cancer specimens, adding TCGA data concerning also other gene analysis (*GSTP1*, *TKT*, and *ERG*) in order to understand their potential use of this axis as biomarker in prostate cancer.

Materials and Methods

Patients

A total of 72 prostate cancer patients who underwent surgical resection in Division of Urology, Department of Translational Research, at Pisa University between 2010 and 2015 were retrospectively selected. Histological diagnoses were independently formulated by PF, according to the World Health Organization classification. Clinic-pathological characteristics were collected whenever available for all the patients. Our study was conducted in accordance with the ethical standards of our institutional research committee and with the 1964 Helsinki declaration; all the patients gave their informed consent to the molecular analyses.

The Cancer Genome Atlas (TCGA) database. From the TCGA data portal (<http://tcga.cancer.gov/>; accessed December 2017), we extracted *c-myc*; *HIF-1 α* ; *GSTP1*, *TKT*, and *ERG* expression together with the corresponding clinical-pathological characteristics and survival data for 497 prostate cancer patients.

RNA isolation

Total RNA were isolated from a representative area selected and marked on the surface of 5 micron sections of formalin-fixed, paraffin-embedded (FFPE) tissues using the miRNeasy FFPE Kit (Qiagen Inc., Hilden, Germany) according to the manufacturer's instructions. The quality and concentration of RNA was assessed using a NanoDrop spectrophotometer (Thermo-Scientific, Wilmington, Del).

c-myc and HIF-1 α mRNA expression

A total of 600 ng of total RNA was used to synthesize cDNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA) in a reaction volume of 20 μ l. Simultaneous quantification of the expression level of *c-myc* and *HIF-1 α* with real-time PCR technology (qPCR) was performed in 72 prostate cancer specimens. Quantification was carried out in triplicate using the Rotor Gene Sybr Green PCR Kit (Qiagen) on a Rotor Gene 6000 (Qiagen) instrument. The following primers were used for qPCR: for *c-myc*, forward primer: 5'-

CCTCAACGTTAGCTTCACCAAC-3' and reverse primer: 5'-CTGCTGGTAGAAGTTCTCCTC-3'); for *HIF-1 α* , forward primer: 5'-TTTAGGCCGCTCAATTTATGA-3' and reverse primer: 5'-TCCTGTGGTGACTTGTCCCTT-3'); and for *beta-Actin*, forward primer: 5'-CCAACCGCGAGAAGATGA-3' and reverse primer: 5'-CCAGAGGCGTACAGGGATAG-3'. The threshold cycle (Ct) and baselines were determined by the manual settings. Expression was calculated by relative quantification using *beta-Actin* as reference control for *c-myc* and *HIF-1 α* . Fold expression changes were determined by the $2^{-\Delta\Delta Ct}$ method, using a pool of 12 non-cancerous tissues as a calibrator group; the analysis was performed by the DataAssistTM software (Applied Biosystems, Foster City, California, USA).

Statistical analysis

Differential expression was determined by applying the non-parametric Wilcoxon test in order to determine the association between mRNAs expression and the clinic-pathological parameters. Survival analyses were performed using the Kaplan-Meier method with log-rank test and the Cox proportional hazard model. Statistical analyses were performed using JMP10 software (SAS, Milan, Italy), and a two-tailed p-value <0.05 was considered significant.

Results

Patient characteristics

This study was conducted in 72 patients with prostate cancer, with a median age at diagnosis of 67 years (range: 51-78, mean: 66.4 years). Most of the tumors were pT2c (48 cases), 12 tumors were pT3a, 3 cases were pT2b, and there were 4 cases for pT2a and 5 for pT3b. Regarding the Gleason score there was only 1 case with score 9, there were 8 cases with score 8 (4+4 in 7 cases, and 5+3 in 1 case), 35 tumors with Gleason score 7 (3+4 in 28 cases, and 4+3 in 8 cases), and 27 cases with score 6.

c-myc and HIF-1 α mRNA expression in our prostate cancer samples

We quantified *c-myc* and *HIF-1 α* mRNA expression, normalized to the β -*actin* housekeeping gene, using real-time qPCR. The samples were divided into high and low expression groups based on the median fold-change value (265.87 for *c-myc* and 2.24 for *HIF-1 α*). *C-myc* mRNA expression was low in 36/72 (50%) cases, as well as *HIF-1 α* in 36/72 (50%) cases. We determined whether *c-myc* and *HIF-1 α* expression were correlated with the main clinic-pathological characteristics, but no statistically significant associations were observed (Table 1).

Focusing on the relationship between *c-myc* and *HIF-1 α* expression, we found that high *c-myc* level was significantly associated with *HIF-1 α* elevated expression (chi-square test, $p=0.0008$). Figure 1 showed that samples with a low *HIF-1 α* level expression displayed lower *c-myc* mRNA levels (270.17 fold change value \pm 76.99) than samples with high *HIF-1 α* score (650.9 \pm 77) (t-test, $p=0.0008$).

TCGA data analysis.

A cohort of 497 prostate cancer patients from TCGA database was further analyzed, in order to validate our findings and to add more data on a larger population. The samples were divided into high and low expression groups based on the median value of *c-myc* and *HIF-1 α* in a first step, then of *GSTP1*, *TKT*, and *ERG* expression.

Statistical analysis of 497 TCGA prostate cancer specimens confirmed the strong association (chi square test, $p=0.0005$) of *c-myc* and *HIF-1 α* expression levels, as we found in our series.

To find the potential link between *c-myc* and others prostate cancer markers, we analyzed the relationship with *GSTP1*, *TKT*, and *ERG* expression. As first result, we found that high *c-myc* levels were significantly associated with low *GSTP1* expression (chi square test, $p=0.01$). Figure 2 showed that samples with low *GSTP1* expression displayed higher *c-myc* mRNA levels (28.379.475 mean value \pm 1.063.536) than samples with high *GSTP1* score (22.089.901 mean value \pm 1.061.399) (t-test, $p<0.0001$).

Then, increased *c-myc* expression was found to be associated with high *TKT* expression (chi square test, $p<0.0001$); moreover, high *TKT* levels were found in TCGA samples with low mean of *GSTP1* mRNA (chi square test, $p<0.0001$), as shown for *c-myc*, and with *ERG* increased expression (chi square test, $p=0.02$). Finally, samples with low *GSTP1* expression displayed higher *ERG* mRNA levels (35.935.827 mean value \pm 2.240.848) than samples with high *GSTP1* score (18.811.341 mean value \pm 2.236.344), as above shown for *c-myc* (t-test, $p<0.0001$).

Discussion

Prostate cancer is extremely heterogeneous, with a wide range of prognosis, and a consequent difficulty in discriminating between indolent and aggressive tumors. PSA serum level and Gleason grading on histological specimens are currently the classical prognostic factor, but they are often unable to predict a correct disease progression. Advances in molecular technologies analysed multiple pathways involved in prostate cancer, helping to identify new markers and modalities of treatment; however, simultaneous multiple markers analysis rather than the study of a single factor may have high robustness and the discovery of an hypothetic targetable axis may be of great use in clinical practice of prostate cancer.

Myc was one of the top genes overexpressed in human prostate cancer tissues [19-26], and the activation of this proto-oncogene seems to be one of the earliest somatic molecular alterations in prostate cancer [1]. However, several data in literature showed that c-myc is essential not only for tumor initiation but also for progression and tumor maintenance [27-33].

Even if c-myc expression is altered in ~70% of human tumors, the mechanism responsible for it is still largely unclear in each cancer type [34] as well as the c-myc target genes in prostate tumors are also unknown. In this work we focused on several genes in order to have a better identification of c-myc target genes and a comprehensive knowledge of the c-myc-related tumorigenesis for the development of new therapeutic strategies.

Overexpression of c-myc enhances and synergizes with HIF-1 α stabilization and accumulation in hypoxic microenvironment in order to promote cell proliferation [35]. Hypoxia and the adaptive changes low oxygen-induced have been involved in genetic instability [36-37] and increase of mutations frequency [38].

The present study started with the investigation of *c-myc* and *HIF-1 α* expression level in our seventy-two prostate cancer samples, confirming their strong associations in oncogenic conditions. Moreover, further analysis on a cohort of 497 prostate cancer patients from the TCGA database confirmed our findings on a larger population and also using a different transcriptome-based technology, such as Illumina HiSeq quantification.

Myc is known to directly and indirectly regulate the transcription of numerous genes and pathways; *GSTP1*, *TKT*, and *ERG* are important players in prostate cancer, but the way of their interactions is not yet clear as well as their

relationship with *c-myc*. Our study suggested the notion of a putative axis, involving *c-myc*; *HIF-1 α* ; *GSTP1*, *TKT*, *ERG*, which should represent a target in prostate cancer.

GSTP1, an important member of glutathione S-transferase (GST)s family, contributes to the regulation of cell proliferation and so is one of the most largely investigated tissue biomarker in several malignancies, including prostate cancer. The regulation of the *GSTP1* expression level may help control the progress of prostate cancer, but it is not yet clear how *GSTP1* plays its protective role. Wang et al [8] recently reported that *GSTP1* overexpression inhibits the viability and motility of prostate cancer *in vitro* and *in vivo* through targeting *myc*. TCGA data analysis in this study showed an activation of *c-myc* associated with *GSTP1* downregulation; oncogenic *myc* deregulation may promote neoplastic transformation by disrupting *GSTP1* tumor suppressor gene function.

C-myc is a transcription factor able to regulate several genes [39-41] and its deregulation in cancer commonly involves different signaling pathways [42]. Metabolic reprogramming has recently been recognized as a hallmark of cancer [43], and deregulated in several tumours [44]. Silencing of *TKT* induced cell cycle arrest as well as overexpression correlated with poor prognosis in breast cancer patients [9], suggesting that *TKT* could be coordinately modulated as part of a central metabolic reprogramming.

In this view, we focused our attention on *TKT* in order to investigate for the first time its role to achieve a fully malignant prostate phenotype and the putative regulation by *c-myc*. Our analysis of TCGA samples showed an association between *TKT* expression and *c-myc*, suggesting that *myc* deregulation in prostate cancer may increase *TKT* levels while disrupting *GSTP1* protective function, as demonstrated by high *TKT* levels in TCGA samples with low *GSTP1* expression.

The *ERG* oncogene is activated in more than 50% of prostate cancer cases, generally through a gene fusion [45], and much attention has been recently focused on it [46-47]. In the current study we looked into the possibility that *ERG* could be involved in metabolic reprogramming in prostate cancer along with *GSTP1* downregulation and *TKT* activation, as suggested by the association we found between low *GSTP1* expression and high *ERG* and *TKT* mRNA levels.

In conclusion, our findings suggested that the dysregulated expression of *c-myc* in prostate cancer could also synergize with other genes, such as *HIF-1 α* ; *GSTP1*, *TKT*, *ERG* (Figure 3) and the balance among these factors in turn would induce cellular proliferation and tumorigenesis; the potential of this axis as diagnostic marker and therapeutic target may have a clinical role in the pathogenesis, development and progression of prostate cancer.

Authors' contributions

Boldrini, and Faviana: project development, data analysis and manuscript writing. Giordano Mirella: data collection. Farci: other (prostate cancer diagnosis). Bartoletti, Manassero and Selli: other (prostate surgery). Panichi Marco and Galli Luca: other (follow-up).

Conflict of Interest

The authors declare that they have no conflict of interest.

Research involving human participants

For this retrospective study formal consent is not required.

References

1. Gurel B, Iwata T, Koh CM, et al. (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. *Mod Pathol* 21:1156-1167
2. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC (2005) Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. *Cancer* 103:1186-1194
3. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM (2010) MYC and Prostate Cancer. *Genes Cancer* 1:617-628

4. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. *Lancet Oncol* 9:342–351
5. Gravdal, K, Halvorsen O J, Haukaas SA, Akslen LA (2009) Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. *Cancer Res* 69:4708–4715
6. Ranasinghe, WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, Shulkes A, Baldwin GS, Patel O (2013) The role of hypoxia-inducible factor 1alpha in determining the properties of castrate-resistant prostate cancers. *PLoS ONE* 8:e54251.
7. Semenza GL (2003) Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 3:721–732
8. Wang XX, Jia HT, Yang H, Luo MH, Sun T (2017) Overexpression of Glutathione S-transferase P1 inhibits the viability and motility of prostate cancer via targeting MYC and inactivating the MEK/ERK1/2 pathways. *Oncol Res* Jun 19 (Epub ahead of print)
9. Benito A, Polat IH, Noé V, Ciudad CJ, Marin S, Cascante M (2017) Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. *Oncotarget* 8:106693-106706

10. Hernández S, Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Salido M, Fumadó L, Serrano L, Cecchini L, Serrano S, Lloreta J (2016) Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. *Prostate* 76:854-865
11. Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, et al (2008) Complex patterns of ETS gene alteration arise during cancer development in the human prostate. *Oncogene* 27:1993-2003
12. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. *Am J Surg Pathol* 31:882-888
13. Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA (2014) TMPRSS2: ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. *J Clin Oncol* 32:206–211
14. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, et al (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. *Oncogene* 26:4596–4599
15. Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T (2008) TMPRSS2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. *Clin Cancer Res* 14:3395-3400
16. Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ (2012) ERG immunohistochemistry is not predictive for PSA recurrence,

local recurrence or overall survival after radical prostatectomy for prostate cancer. *Mod Pathol* 25:471–479

17. Hägglöf C, Hammarsten P, Strömvall K, Egevad L, Josefsson A, Stattin P, Granfors T, Bergh A (2014) TMPRSS2- ERG expression predicts prostate cancer survival and associates with stromal biomarkers. *PLoS One* 9:e86824
18. Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Lorente JA, Fumado L, Serrano L, Serrano S, Lloreta J, Hernández S (2015) Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. *Prostate* 75:1216-1226
19. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa (2010) Oxygen in stem cell biology: a critical component of the stem cell niche. *Cell Stem Cell* 7:150–161
20. Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. *Cell* 129:465–472
21. Palma CS, Tannous MA, Malta TM, Russo EMS, Covas DT, Picanço-Castro V (2013) Forced expression of OCT4 influences the expression of pluripotent genes in human mesenchymal stem cells and fibroblasts. *Genetics and Molecular Research* 12:1054–1060
22. Pelengaris S, Khan M, Evan G I (2002) Suppression of Myc induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. *Cell* 109:321–334
23. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, et al (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. *Mol Cell* 9:1031–1044

24. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 441:437–443
25. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, et al (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. *Genes Dev* 20:557–570
26. Dang CV, Kim JW, Gao P, Yustein J (2008) The interplay between MYC and HIF in cancer. *Nat Rev Cancer* 8:51–56
27. Gabay M, Li Y, Felsher DW (2014) MYC activation is a hallmark of cancer initiation and maintenance. *Cold Spring Harb Perspect Biol* 4
28. Arvanitis C, Felsher DW (2006) Conditional transgenic models define how MYC initiates and maintains tumorigenesis. *Semin Cancer Biol* 16:313–317
29. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. *Nature* 431:1112–1117
30. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. *Mol Cell* 4:199–207
31. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. *Science* 297:102–104
32. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW (2003) Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. *Blood* 101:2797–2803

33. Beer S, Zetterberg A, Ihrle RA, McTaggart RA, Yang Q, Bradon N, et al (2004) Developmental context determines latency of MYC-induced tumorigenesis. *PLoS Biol* 2:e332
34. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer (2003) *Oncogene* 22:9007–9021
35. Doe MR, Ascano J, Kaur M, Cole MD (2012) Myc post-transcriptionally induces HIF1 protein and target gene expression in normal and cancer cells. *Cancer Res* 72:949–957
36. Huang LE, Bindra RS, Glazer PM, Harris AL (2007) Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression. *J Mol Med* 85:139–148
37. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. *Nat Rev Cancer* 8:180–192
38. Reynolds TY, Rockwell S, Glazer PM (1996) Genetic instability induced by the tumor microenvironment. *Cancer Res* 56:5754–5757
39. Grandori C, Cowley SM, James LP, Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. *Annu Rev Cell Dev Biol* 16:653–699

40. Nasi S, Ciarapica R, Jucker R, Rosati J, Soucek L (2001) Making decisions through Myc. *FEBS Lett* 490:153–162
41. Albiñ A, Johnsen JI, Henriksson MA (2010) MYC in oncogenesis and as a target for cancer therapies. *Adv Cancer Res* 107:163–224
42. Eilers M, Eisenman RN (2008) Myc's broad reach. *Genes Dev* 22:2755–2766
43. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. *Cell* 144:646–674
44. Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, Law CT, Wong CM, Cai Z, Wong CC, Ng IO (2016) Transketolase counteracts oxidative stress to drive cancer development. *Proc Natl Acad Sci U S A* 113:E725-34
45. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 310:644-648
46. Adamo P, Porazinski S, Rajatileka S, Jumbe S, Hagen R, Cheung MK, Wilson I, Lodomery MR (2017) The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells. *Oncol Lett* 14:5605-5610

47. Adamo P, Lodomery MR (2016) The oncogene ERG: a key factor in prostate cancer. *Oncogene* 35:403-414

Figure Legends

Figure 1: Relationship between *c-myc* and *HIF-1 α* mRNA expression (t-test, $p=0.0008$).


Figure 2: Relationship between *c-myc* and *GSTP1* mRNA expression (t-test, $p < 0.0001$).


Figure 3: Balance among dysregulated expression of *c-myc* and other genes, such as *HIF-1 α* ; *GSTP1*, *TKT*, *ERG*: a potential axis as diagnostic marker and therapeutic target in prostate cancer.


Table 1. Correlations between *c-myc* and *HIF-1 α* expression level and the main clinicopathological characteristics of our 72 prostate cancer patients.

Characteristic	<i>c-myc</i> expression ^a		p-value ^b	<i>HIF-1α</i> expression ^a		p-value ^b
	Low	High		Low	High	
Age						
≤67 years	17	24	0.09	21	20	0.81
>67 years	19	12		15	16	
TNM						
T2 (T2a-T2b-T2c)	27	28	0.78	28	27	0.78
T3 (T3a-T3b)	9	8		8	9	
Gleason score						
6	16	11	0.47	14	13	0.92
7 (3+4-4+3)	16	20		18	18	
8,9 (4+4-5+3, 4+5)	4	5		4	5	

^aValues are shown as n. ^bp-values are assessed by χ^2 test.







Pisa, July 25th, 2018

Dear Editor-in-Chief, *PATHOLOGY & ONCOLOGY RESEARCH*

We wish to submit to you the manuscript titled "*C-MYC, HIF-1 α , ERG, TKT, and GSTP1: an axis in prostate cancer?*", which was authored by myself, Bartoletti, Giordano, Manassero, Panichi, Galli, Farci, and Faviana for your kind consideration for publication in *Pathology & Oncology Research*. We performed a simultaneous quantification of the expression level of *c-myc* and *HIF-1 α* mRNA with Real-Time PCR technology in seventy-two prostate cancer specimens. A cohort of 497 prostate cancer patients from The Cancer Genome Atlas (TCGA) database was further analyzed, in order to test our hypothesis.

Our data present novel insights into a potential value of *HIF-1 α* and *c-myc* as putative biomarkers in prostate cancer; moreover TCGA data analysis showed a putative crosstalk between *c-myc*, *HIF-1 α* , *ERG*, *TKT*, and *GSTP1*, suggesting a potential use of this axis in prostate cancer.

The manuscript conforms to the journal's policies. The article is original, is not under consideration elsewhere and has not been previously published. Its content has not been anticipated by any other publication. All authors have approved the manuscript for submission and they have no conflict interests to declare.

We hope that you find our data interesting and consider the manuscript for publication in *Pathology & Oncology Research*.

Thank you very much for your kind attention.

Sincerely yours,

Laura Boldrini

Dr. L. Boldrini, Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa
Anatomic Pathology, via Roma, 67,
56126 Pisa, Italy
Phone: +39-050-997849
Fax: +39-050-992396
E-mail: laura.boldrini@med.unipi.it